Ep. 38: Why A Mini-Correction Would Be Healthy With Patrick Healey
Investing With IBD
00:00
Acadia Pharmaceuticals: A Biotech Stock That Could Be a Blockbuster
The debate is over whether it's going to be for primary preventative measures or secondary and how big that population can be. And there's a lot of watchful eyes on that FDA decision going into the end of the year. Acadia pharmaceuticals developed drugs to treat psychosis related to various indications, Parkinson's disease, dementia, schizophrenia, Alzheimer's. They are currently approved for Parkinson's disease psychosis.
Transcript
Play full episode
